Disclaimer: The information provided in this article is meant for general informational purposes only and should not be considered as professional or legal advice. We do not guarantee the completeness, accuracy, reliability, or suitability of the information in this article. We strongly recommend seeking professional guidance that suits your individual circumstances. |
GLP-1 is not a supplement ingredient
GLP-1 (Glucagon-like peptide-1) is a prescription-only peptide drug used for type 2 diabetes management and, more recently, weight loss (think Ozempic® or Wegovy®). Because it's classified as a drug by the Food and Drug Administration (FDA), it cannot be added to dietary supplements or marketed as one.
It's not the word, it's the implied claim
The risk isn't simply that "GLP" or "GLP-1" appears somewhere on your label or product page. The risk is when that language, combined with the rest of your claims, implies your supplement works like the drug: suppressing appetite, triggering GLP-1 receptor activity, or producing drug-comparable weight loss.
That's different from a normal structure/function claim, which describes how your product supports the body's normal processes. For example, "supports normal digestion" or "supports metabolic wellness" without claiming to replicate, enhance, or substitute for a prescription drug's mechanism of action.
Why implied drug claims are risky
Even without literally including the drug, using "GLP-1" or "GLP" in a way that suggests drug-like action is risky. Here's why:
Regulatory red flag: The FDA may view claims that suggest your product mimics or replicates GLP-1 drug activity as an implied drug claim. This is especially sensitive in the weight loss category.
Misleading to consumers: The FTC could consider it deceptive marketing if shoppers reasonably assume the product works like a GLP-1 drug, when it does not.
Brand liability: As the brand owner, you're fully responsible for the claims on your packaging and marketing. If regulators take issue, it's your business on the line.
What's generally lower-risk
Referencing GLP-1 in a factual, non-mechanistic way is generally lower risk than claiming drug-like effects. For example:
Describing your product as supporting people who are managing dietary or appetite changes (without saying why those changes are happening, or claiming to cause them).
Structure/function claims like "supports normal digestion" or "helps maintain healthy energy levels."
Ingredient-focused benefits (e.g., "with ginger and peppermint to support digestive comfort").
What still isn't safe, regardless of phrasing: any suggestion that your product activates GLP-1 receptors, suppresses appetite the way the drug does, or produces comparable weight-loss results.
Safer alternatives for positioning your product
You don't need drug-comparison language to market your product effectively. Instead, focus on benefits you can confidently stand behind:
Structure/function claims like "supports normal metabolism" or "helps maintain healthy energy levels."
Ingredient-focused benefits (e.g., "with green tea extract for antioxidant support").
Lifestyle positioning around wellness, balance, or supporting healthy habits.
These approaches let you highlight your product's value, including relevance to people managing appetite or dietary changes, without creating the impression that it acts like a prescription drug.
And remember, when it comes to weight management, it's always a good idea to remind your customers that the best results come from combining supplements with a healthy diet and active lifestyle.
Bottom line
You're free to make the final decision on your label, but our strong advice is: don't imply that your product replicates, enhances, or substitutes for the GLP-1 drug's action. Referencing "GLP-1" in a purely descriptive, non-mechanistic way carries less risk than making mechanism or outcome comparisons — but any use of the term still deserves careful legal review before it goes on a label. As with any claim you make, you are responsible for ensuring it is truthful, not misleading, and substantiated with competent and reliable evidence before it goes to market. The risks of getting this wrong far outweigh any short-term marketing benefit.